Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.
OBJECTIVE
The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved.


METHODS
We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC.


RESULTS
Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan.


CONCLUSIONS
The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.
Nakamura
Minoru
M
Department of Hepatology, Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Nagasaki University Graduate School of Biomedical Sciences, Kubara 2-1001-1, Omura, Nagasaki 856-8562, Japan. nakamuram@nmc.hosp.go.jp
Shimizu-Yoshida
Yuki
Y
Takii
Yasushi
Y
Komori
Atsumasa
A
Yokoyama
Terufumi
T
Ueki
Toshihito
T
Daikoku
Manabu
M
Yano
Koji
K
Matsumoto
Takehiro
T
Migita
Kiyoshi
K
Yatsuhashi
Hiroshi
H
Ito
Masahiro
M
Masaki
Naohiko
N
Adachi
Hiroshi
H
Watanabe
Yukio
Y
Nakamura
Yoko
Y
Saoshiro
Takeo
T
Sodeyama
Takeshi
T
Koga
Michiaki
M
Shimoda
Shinji
S
Ishibashi
Hiromi
H
D000906:Antibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000097:blood / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000502:physiology; D008297:Male; D008562:Membrane Glycoproteins / Q000276:immunology*; D008875:Middle Aged; D028861:Nuclear Pore Complex Proteins; D009687:Nuclear Proteins / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology; D011336:Probability; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D000906:Antibodies; D015415:Biomarkers; D008562:Membrane Glycoproteins; C063865:NUP210 protein, human; D028861:Nuclear Pore Complex Proteins; D009687:Nuclear Proteins; D010446:Peptide Fragments; D014580:Ursodeoxycholic Acid